Stockscreener 앱 받기
35.26
5.51%
1.84
시간 외 거래:
35.06
-0.20
-0.57%
Cogent Biosciences Inc 주식(COGT)의 최신 뉴스
Can Cogent Biosciences Inc. stock weather global recessionDividend Hike & Weekly Consistent Profit Watchlists - newser.com
Will Cogent Biosciences Inc. stock maintain dividend yieldInflation Watch & Free Risk Controlled Daily Trade Plans - newser.com
Cogent Biosciences (NASDAQ:COGT) Shares Gap DownWhat's Next? - MarketBeat
Cogent Biosciences Shares Slip After Announcing $500 Million Fundraising Plan - MSN
Cogent Biosciences stock falls after pricing $500 million offerings By Investing.com - Investing.com Australia
Cogent Biosciences stock falls after pricing $500 million offerings - Investing.com India
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $34.00 - MarketBeat
Cogent Biosciences (COGT) Boosts Stock Offering to $300 Million - GuruFocus
Cogent Biosciences Raises Nearly $500 Million For Growth - Finimize
Cogent Biosciences Prices $475 Million in Combined Equity, Convertible Notes Offerings - MarketScreener
Cogent Biosciences (COGT) Upsizes Equity Offering to $475.3M - GuruFocus
Day 5 of Gains Streak for Cogent Biosciences Stock with 137% Return (vs. 328% YTD) [11/11/2025] - Trefis
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 - Investing News Network
Cogent Biosciences (NASDAQ: COGT) prices 9,677,420 shares at $31; plus convertible notes - Stock Titan
Cogent Biosciences Prices Public Offerings of Common Stock and Convertible Senior Notes Totaling Approximately $475 Million - Quiver Quantitative
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 - GlobeNewswire Inc.
Is Cogent Biosciences Inc. stock reversal real or fake2025 Market WrapUp & Free Technical Confirmation Trade Alerts - newser.com
Baird Maintains Cogent Biosciences (COGT) Neutral Recommendation - Nasdaq
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $50.00 at Leerink Partners - MarketBeat
Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial - Insider Monkey
Cogent Biosciences (NASDAQ:COGT) Upgraded by Wedbush to "Outperform" Rating - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Upgraded by Stifel Nicolaus to "Buy" Rating - MarketBeat
Comparing Cogent Biosciences Inc. in custom built stock radarsWeekly Profit Report & Growth Focused Entry Reports - newser.com
Cogent Biosciences: Soaring On Blowout GIST DataI Expect More Upside (NASDAQ:COGT) - Seeking Alpha
Cogent Biosciences slips as co eyes capital raise after stock surge - TradingView
Cogent Biosciences (NASDAQ:COGT) Hits New 1-Year High on Strong Earnings - MarketBeat
Baird Maintains Neutral Rating on COGT, Raises Price Target to $34 | COGT Stock News - GuruFocus
Wedbush Upgrades Cogent Biosciences to Outperform From Neutral, Raises Price Target to $38 From $13 - MarketScreener
Leerink Partners Maintains Cogent Biosciences (COGT) Outperform Recommendation - Nasdaq
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - Investing News Network
Assessing Cogent Biosciences (COGT) Valuation After Strong Recent Share Price Surge - simplywall.st
Cogent Biosciences (COGT) Stock Soars with 135% Increase - GuruFocus
Cogent Biosciences stock hits 52-week high at 32.79 USD By Investing.com - Investing.com Australia
Cogent Biosciences’ Phase 3 PEAK Study Success Positions Company for Market Leadership and $1.1 Billion Peak Sales - TipRanks
How Cogent Biosciences Inc. stock benefits from tech adoptionSwing Trade & AI Based Buy/Sell Signal Reports - newser.com
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Cogent Biosciences (COGT) - The Globe and Mail
Cogent Biosciences price target raised to $45 from $30 at Jefferies - TipRanks
Cogent Biosciences (COGT): Assessing Valuation After a 119% One-Day Surge and 316% YTD Gain - Yahoo Finance
Biotech Mergers And Trial Successes Send Shares Higher - Finimize
Cogent Biosciences stock hits 52-week high at 32.79 USD - Investing.com India
Cogent Biosciences (COGT) Launches $400M Public Offerings - GuruFocus
Cogent Biosciences Launches Concurrent Public Offerings Worth $400 Million - MarketScreener
A second win for Cogent pushes the company toward two NDAs - BioWorld MedTech
Cogent Biosciences launches $400 mln equity, convertible deals after stock more than doubles - TradingView
Is Cogent Biosciences’ Bright Future Already Here? - timothysykes.com
COGT: Leerink Partners Raises Price Target to $50.00, Maintains Outperform Rating | COGT Stock News - GuruFocus
Cogent Biosciences announces proposed concurrent public offerings - MSN
Biotech Catapults 119% On A First-In-20-Years Development - Investor's Business Daily
Cogent Hits Mark In Phase III GIST Trial Of Bezuclastinib - Citeline News & Insights
Cogent Biosciences price target raised to $50 from $18 at Leerink - TipRanks
Cogent Biosciences: Promising Outlook with Breakthrough GIST Treatment and Strategic Growth Plans - TipRanks
Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy (COGT) - Seeking Alpha
Cogent Biosciences Stock Surges 136%. Why Investors See Promise in Its Cancer Drug. - Barron's
Cogent Biosciences Shares Rise After Bezuclastinib Combination Improves GIST Survival Rate in Phase 3 Trial - MarketScreener
Cogent Biosciences Shares Surge 135% After Strong Cancer Drug Trial Results - Nasdaq
Cogent Biosciences (COGT) Sees Ratings Boost Following Promising Trial Results - GuruFocus
Cogent Biosciences (COGT) Stock Soars 127% After Positive Phase 3 Cancer Drug Trial Results - parameter.io
Cogent Biosciences (COGT) Shares Skyrocket Over 100% - GuruFocus
Why Is Cogent Biosciences Stock Trading Higher Today?Cogent Biosciences (NASDAQ:COGT) - Benzinga
Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On MondayCogent Biosciences (NASDAQ:COGT), e.l.f. Beauty (NYSE:ELF) - Benzinga
1.62%
자본화:
|
볼륨(24시간):